Form 4 for LLY Lilly (Eli)
Accepted 2023-02-14 00:00:00 ET · period of report 2023-02-10 · accession 0000059478-23-000055 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-14 | 2023-02-10 | LLY | Mason Michael B | EVP, Pres, Lilly Diabetes | A - Grant | $345.12 | +8,023 | 39.3K | +26% | +$2.77M |
| D | 2023-02-14 | 2023-02-10 | LLY | Mason Michael B | EVP, Pres, Lilly Diabetes | A - Grant | $0.00 | +3,490 | 3,490 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-10 | A | A | 8,023 | $345.12 | 39,284 | D | — | — | |
| 2 | Derivative | Restricted Stock Unit | 2023-02-10 | A | A | 3,490 | $0.00 | 3,490 | D | — · 2024-02-01 to 2024-02-01 | 3,490 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |